| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Christine A Pratilas | Q102380741 |
| P2093 | author name string | David B Solit | |
| P2860 | cites work | Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients | Q24294421 |
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 | ||
| Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP | Q24305011 | ||
| KSR, a novel protein kinase required for RAS signal transduction | Q24310039 | ||
| A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene | Q24647664 | ||
| A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function | Q24651242 | ||
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 | ||
| Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer | Q24685746 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Phosphorylation and regulation of Raf by Akt (protein kinase B) | Q28138863 | ||
| Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP | Q28144497 | ||
| Mechanisms of regulating the Raf kinase family | Q28183716 | ||
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 | ||
| Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase | Q28269621 | ||
| Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization | Q28287759 | ||
| The complexity of Raf-1 regulation | Q28305850 | ||
| Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 | ||
| KSR modulates signal propagation within the MAPK cascade | Q28609154 | ||
| PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo | Q28609356 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma | Q33384029 | ||
| A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer | Q34106382 | ||
| Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus | Q34253429 | ||
| 14-3-3: modulators of signaling proteins? | Q34324416 | ||
| Clinical experience of MEK inhibitors in cancer therapy | Q34595700 | ||
| Distinct requirements for Ras oncogenesis in human versus mouse cells | Q34787097 | ||
| 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition | Q35469515 | ||
| Unlocking the code of 14-3-3. | Q35748302 | ||
| Modulation of signalling by Sprouty: a developing story | Q35790325 | ||
| Targeting the mitogen-activated protein kinase cascade to treat cancer | Q35968411 | ||
| Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses | Q36299131 | ||
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 | ||
| BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines | Q36732681 | ||
| Dual-specificity MAP kinase phosphatases (MKPs) and cancer | Q37106291 | ||
| (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway | Q37112466 | ||
| Genetic predictors of MEK dependence in non-small cell lung cancer | Q37113682 | ||
| Three human transforming genes are related to the viral ras oncogenes | Q37608532 | ||
| SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant | Q38337665 | ||
| Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer | Q38445646 | ||
| Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. | Q39782693 | ||
| Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors | Q39926451 | ||
| BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins | Q39954401 | ||
| Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 | ||
| Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms | Q40131378 | ||
| Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. | Q40314354 | ||
| Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade | Q40353963 | ||
| Regulation of Raf-1 by direct feedback phosphorylation. | Q40467820 | ||
| The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. | Q40519865 | ||
| Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation | Q41822622 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers | Q43136770 | ||
| Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 | ||
| Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. | Q47745775 | ||
| Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition | Q50335943 | ||
| RAS oncogenes: the first 30 years. | Q55036584 | ||
| Signal transduction. How receptors turn Ras on. | Q55066288 | ||
| BRAF and RAS mutations in human lung cancer and melanoma | Q78598197 | ||
| Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration | Q80194445 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3329-3334 | |
| P577 | publication date | 2010-05-14 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response | |
| P478 | volume | 16 |
| Q91787280 | A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma |
| Q36844361 | A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity |
| Q55025521 | A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. |
| Q39395597 | A quantitative structure-activity relationship (QSAR) study of some diaryl urea derivatives of B-RAF inhibitors |
| Q35237394 | An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance |
| Q28534259 | Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia |
| Q34375732 | Are oncogenes sufficient to cause human cancer? |
| Q36822126 | Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition |
| Q21198860 | B-Raf and the inhibitors: from bench to bedside |
| Q64064520 | Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced - or -mutated melanoma |
| Q37899757 | Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization |
| Q38692782 | Cantharidin suppressed breast cancer MDA-MB-231 cell growth and migration by inhibiting MAPK signaling pathway |
| Q29048651 | Case-specific potentiation of glioblastoma drugs by pterostilbene |
| Q30277902 | Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas |
| Q28541174 | Computational analyses of synergism in small molecular network motifs |
| Q34149419 | Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish |
| Q38803566 | DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models |
| Q38333998 | Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups |
| Q34289063 | Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling |
| Q35873526 | ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. |
| Q58550380 | Electrochemically Reduced Water Delays Mammary Tumors Growth in Mice and Inhibits Breast Cancer Cells Survival |
| Q46830676 | Endogenous Molecular-Cellular Network Cancer Theory: A Systems Biology Approach |
| Q37119697 | Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer |
| Q35675442 | Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches. |
| Q39574037 | Expression of KITENIN in human colorectal cancer and its relation to tumor behavior and progression |
| Q51150179 | Extracellular signal-regulated kinase (ERK) expression and activation in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. |
| Q44951464 | Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer. |
| Q48525606 | Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss |
| Q35956277 | GABAB receptor complex as a potential target for tumor therapy |
| Q53086558 | Genomic and transcriptomic profiles and in vitro resistance to mitoxantrone and idarubicin in pediatric acute leukemias. |
| Q34049618 | Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. |
| Q35619558 | Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing |
| Q54964710 | Isoform-selective activity-based profiling of ERK signaling |
| Q41616075 | Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer |
| Q38092584 | MEK inhibitors as a chemotherapeutic intervention in multiple myeloma |
| Q39007170 | MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition |
| Q36654285 | Mitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survival |
| Q49438304 | Mitogen-activated protein kinase signaling pathway in oral cancer |
| Q35703167 | Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI. |
| Q39162638 | Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging. |
| Q38936778 | Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress |
| Q34669370 | Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance |
| Q37110450 | OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway. |
| Q37799845 | PLX4032: does it keep its promise for metastatic melanoma treatment? |
| Q38256348 | Profile of selumetinib and its potential in the treatment of melanoma |
| Q35956840 | Prognostic value of RKIP and p-ERK in gastric cancer |
| Q28085240 | Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy? |
| Q34228544 | Quantifying factors for the success of stratified medicine |
| Q37718332 | Quantitative implementation of the endogenous molecular-cellular network hypothesis in hepatocellular carcinoma |
| Q28289378 | RAF protein-serine/threonine kinases: Structure and regulation |
| Q42157466 | RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it. |
| Q92656933 | RASA1-dependent cellular export of collagen IV controls blood and lymphatic vascular development |
| Q39578288 | RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway |
| Q39412662 | RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer |
| Q37841746 | Receptor tyrosine kinases and their activation in melanoma. |
| Q28392677 | Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase |
| Q34497045 | Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma |
| Q37953290 | Ricin and Shiga toxins: effects on host cell signal transduction |
| Q34966603 | Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q53591568 | Sarsaparilla (Smilax Glabra Rhizome) Extract Inhibits Cancer Cell Growth by S Phase Arrest, Apoptosis, and Autophagy via Redox-Dependent ERK1/2 Pathway. |
| Q37992502 | Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium |
| Q38400912 | Signal transduction in cancer |
| Q38730327 | Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells |
| Q38487106 | Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development |
| Q34356841 | Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib |
| Q39173195 | Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations |
| Q37072842 | Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics. |
| Q34222257 | Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma |
| Q38155122 | Targeting DUSPs in glioblastomas - wielding a double-edged sword? |
| Q36278239 | Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy |
| Q37945533 | The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? |
| Q37996420 | The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. |
| Q35999467 | The two faces of FBW7 in cancer drug resistance. |
| Q42262009 | Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma |
| Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |
| Q39262217 | Therapeutic strategies for targeting ras proteins |
| Q40104707 | To Eat and to Be Eaten: Mutual Metabolic Adaptations of Immune Cells and Intracellular Bacterial Pathogens upon Infection |
| Q38083794 | Trametinib (GSK1120212) in the treatment of melanoma |
| Q28276886 | Vemurafenib: the first drug approved for BRAF-mutant cancer |
| Q37359696 | [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models |
| Q87233254 | [Predictive biomarkers for tumor-relevant signaling pathways in molecular pathology] |
| Q42017919 | c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway |
Search more.